Mucopolysaccharidosis Clinical Features

Mucopolysaccharidoses (MPS) are a prominent group of genetic lysosomal storage diseases. The intralysosomal accumulation of glycosaminoglycans caused by several different enzyme deficiencies induces a cascade of responses that affect cellular functions and the preservation of the extra-cellular matrix.

Taken together, the effects of these deficiencies result in the appearance of chronic and progressive syndromes that produce a wide array of clinical manifestations in multiple organ systems. While the disease may not always be apparent at birth, manifestations of the disease develop with age as more cells become damaged by the accumulation of cell materials.

An Inside look at Mucopolysaccharidosis Type I (MPS I)

Dominant signs and symptoms

Individuals affected by mucopolysaccharidosis share many similar symptoms, namely the involvement of multiple organ systems, distinctive facial features, as well as abnormalities of the skeleton, particularly within the joints. The age of the onset and severity of clinical presentation may vary significantly both within and among the seven major types of mucopolysaccharidoses.

Patients are normal at birth, although some (mostly those with MPS 7) can present with hydrops fetalis. Hydrops fetalis is a severe and challenging fetal condition defined as the excessive accumulation of fluid within the fetal extravascular compartments and body cavities resulting in edema, effusions, and ascites. In most of the other cases, clinical signs appear after several months or years.

Organ involvement depends on the type of mucopolysaccharidosis. For example, patients with MPS 6 have severe skeletal and heart disease without cognitive impairment, whereas those with MPS 4 have serious skeletal dysplasia and joint hypermobility. Comparatively, patients with MPS 3 have little somatic involvement, but early and severe neurological impairment.

A wide phenotypic spectrum can be observed within the same type of mucopolysaccharidosis as well. For example, early involvement of many organs and functions including the cardiac, skeletal, auditory, visual, and neurological systems are practically the rule in the severe form of MPS 1 called Hurler syndrome. On the other hand, patients with the attenuated form of MPS 1 called Scheie syndrome can present with one isolated symptom or sign in the third decade of life.

Musculoskeletal involvement is a common feature in all types of mucopolysaccharidoses. Differentiation of these disorders from the inflammatory arthritides is essential if early treatment is the end goal. Attention to the characteristics of the musculoskeletal disease and appropriate radiographic investigation facilitates the timely diagnosis and appropriate management of affected individuals.

Vision problems are also a common finding. Glaucomas have been reported in MPS 1 and MPS 6, while cataracts can be found in MPS 3 and MPS 4. Retinal degeneration can occur later in life, resulting in the loss of peripheral vision and night blindness.

Upper airway infections are frequently found in patients with these syndromes, albeit lower airway infections are not that common. Lung infections can be attributed to the narrow trachea and larynx, as well as alterations in chest mobility. Recurrent ear infections and subsequent hearing loss are characteristic of MPS 4.

Prediction of disease severity

Delays in the diagnosis of mucopolysaccharidoses are common, thus many children and young adults will suffer for years with an unrecognized disease. In addition, predicting disease severity is a difficult task, and early recognition of the disease is often hampered by the nonspecific presentation.

Clinicians hoped that analysis of urinary glycosaminoglycan levels would be a useful tool to predict disease severity; however, it was determined that this test cannot be employed as a reliable indicator of severity, even though a higher level can be suggestive of a more severe form of the disease.

Correlations of genotype with phenotype have been curtailed by the rare appearance of mucopolysaccharidoses and a large number of possible mutations, many of which occur only in a single affected family. Therefore, clinical severity associated with missense mutations and other types of mutations has remained difficult to predict for all types of disease.

References

Further Reading

Last Updated: Apr 6, 2021

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2021, April 06). Mucopolysaccharidosis Clinical Features. News-Medical. Retrieved on May 18, 2021 from https://www.news-medical.net/health/Mucopolysaccharidosis-Clinical-Features.aspx.

  • MLA

    Meštrović, Tomislav. "Mucopolysaccharidosis Clinical Features". News-Medical. 18 May 2021. <https://www.news-medical.net/health/Mucopolysaccharidosis-Clinical-Features.aspx>.

  • Chicago

    Meštrović, Tomislav. "Mucopolysaccharidosis Clinical Features". News-Medical. https://www.news-medical.net/health/Mucopolysaccharidosis-Clinical-Features.aspx. (accessed May 18, 2021).

  • Harvard

    Meštrović, Tomislav. 2021. Mucopolysaccharidosis Clinical Features. News-Medical, viewed 18 May 2021, https://www.news-medical.net/health/Mucopolysaccharidosis-Clinical-Features.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.